|
|
|
A RED FLAG FOR LETHAL PROSTATE CANCER
EZH2 Genetic Biomarker detects most aggressive cells, say University of Michigan scientists:
ANN ARBOR, MI - High levels of activity in a gene called EZH2 could be a warning sign of metastatic prostate cancer, according to scientists at the University of Michigan's Comprehensive Cancer Center.
To view entire article:
www.med.umich.edu/opm/newspage/2002/EZH2.htm
UNIVERSITY OF MICHIGAN SCIENTISTS FIND NEW GENETIC MARKER FOR PROSTATE CANCER
More accurate than PSA, gene's protein detected in 95 percent of localized cancer cells:
ANN ARBOR, MI - Using the power of advanced DNA microarray technology, scientists at the University of Michigan Medical School have identified a gene that triggers production of a specific protein in cancerous prostate cells. Because the protein is present in large amounts only in malignant cells and is easily visible when stained, it could improve the accuracy and sensitivity of screening tests for prostate cancer - the second leading cause of cancer-related deaths in men.
To view entire article:
www.med.umich.edu/opm/newspage/2002/prostatemarker.htm
SCIENTISTS FIND PROTEIN THAT CONTROLS PROSTATE CANCER'S SPREAD
University of Michigan team shows RKIP rules key step of metastasis: invasion of blood vessels:
ANN ARBOR, MI - Cancer specialists know that it's not usually prostate cancer itself that kills - it's the spread of the cancer from the prostate to the rest of the body. But relatively little is known about exactly what makes some men's cancers spread, or metastasize, while other tumors stay put.
To view entire article:
www.med.umich.edu/opm/newspage/2003/prostateprotein.htm
DIAGNOSIS OF PROSTATE CANCER
(Contemporary Diagnosis and Management of Diseases of the Prostate)
Prostate cancer does not typically cause symptoms until it is advanced. Urinary symptoms are often initially related locally to prostatic obstruction. Prostate cancer typically arises in the periphery of the prostate, so if it causes significant urethral or ureteral obstruction it is often regionally more advanced. In addition, some patients present with metastatic disease with symptoms of bone pain or systemic symptoms. The early diagnosis of prostate cancre is best achieved by combined digital rectal examination (DRE) and serum prostatic specific antigen (PSA).
Transrectal ultrasound (TRUS)-guided needle biopsy is the most typical and reliable method of diagnosing prostate cancer. The American Cancer Society abnd the American Urological Association recommend the routine use of DRE and PSA in the annual evaluation of asymptomatic men over the age of 50. These 2 tests frequently result in the diagnosis of lower-stage disease. There is no curative treatment for metastatic prostate cancer. Effective treatment is generally limited to prostate cancer that is confined to the prostate.
Both DRE and serum PSA are important in the annual evaluation of men over 50. Approximately one half of the suspicious lesions found on DRE are caused by prostatic cancer. It is important to consider needle biopsy of the prostate in all men who have prostatic abnormalities or rectal abnormalities regardless of the PSA level. Approximately one quarter of men with prostatic cancer may have a serum PSA of less than 4.0, the normal level. This fact demonstrates why both DRE and serum PSA levels are important.
|
|
|
|
|
|
|
